Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI)

• Asıl Yazarlar: Alice T.W. Song (Yazar), Vanderson Rocha (Yazar), Alfredo Mendrone-Júnior (Yazar), Rodrigo T. Calado (Yazar), Gil C. De Santis (Yazar), Bruno D. Benites (Yazar), Carolina Costa-Lima (Yazar), Taiani Vargas (Yazar), Leonardo S. Marques (Yazar), Juliana C. Fernandes (Yazar), Felipe C. Breda (Yazar), Silvano Wendel (Yazar), Roberta Fachini (Yazar), Luiz V. Rizzo (Yazar), José Mauro Kutner (Yazar), Vivian I. Avelino-Silva (Yazar), Rafael R.G. Machado (Yazar), Edison L. Durigon (Yazar), Sylvie Chevret (Yazar), Esper G. Kallas (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Elsevier, 2022-06-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Summary: Background: Administration of convalescent plasma may serve as an adjunct to supportive treatment to prevent COVID-19 progression and death. We aimed to evaluate the efficacy and safety of 2 volumes of intravenous convalescent plasma (CP) with high antibody titers for the treatment of sever...